Search

Your search keyword '"Lam, Robert"' showing total 6 results
Start Over Author "Lam, Robert" Publication Year Range This year
6 results on '"Lam, Robert"'

4. Contributors

Author

Balogun, Oluwafemi O., Banini, Bubu A., Beier, Juliane I., Cheng, Katherine, Corey, Kathleen E., Crocombe, Dominic, Di Bartolomeo, Anna, Do, Albert, Fan, Jian-Gao, Fan, Weiguo, George, Jacob, Goens, Donald, Golabi, Pegah, Henry, Linda, Horn, Paul, Huang, Jee-Fu, Huang, Daniel Q., Ito, Takanori, Johnson-Mann, Crystal N., Jun, Dae Won, Kaya, Eda, Kim, Sun H., Kwo, Paul Y., Lam, Robert, Li, Guanlin, Lim, Joseph K., Lin, Huapeng, Medici, Valentina, Muthiah, Mark, Newsome, Philip N., Ng, Cheng Han, Nguyen, Mindie H., Oh, Joo Hyun, Patton, Heather, Rosenthal, Philip, Shaikh, Emad S., Spencer, Sean, Takahashi, Hirokazu, Teng, Margaret L.P., Tsochatzis, Emmanuel A., Török, Natalie J., Wong, Vincent Wai-Sun, Wong, Grace Lai-Hung, Yang, Rui-Xu, Yeh, Ming-Lun, Yeo, Yee Hui, Yilmaz, Yusuf, Younossi, Zobair M., Yu, Ming-Lung, Zarrinpar, Amir, and Zhang, Xinrong

Published
2024
Full Text
View/download PDF

5. Atomistic Simulation and Measurement of pH dependent Cancer Therapeutic Interactions with Nanodiamond Carrier

Author

Adnan, Ashfaq, Lam, Robert, Chen, hanning, Lee, Jessica, Schaffer, Daniel J., Barnard, Amanda S, Schatz, George C., Ho, Dean, and Liu, Wing Kam

Abstract

In this work, we combine constant-pH molecular dynamics simulations and experiments to provide a quantitative analysis of pH-dependent interactions between doxorubicin hydrochloride (DOX) cancer therapeutic and faceted nanodiamond (ND) nanoparticle carriers. Our study suggests that when a mixture of faceted ND and DOX are dissolved in a solvent, the pH of this solvent plays a controlling role on the adsorption of DOX molecules on the ND. We find that the binding of DOX molecules occurs only at high pH, and requires at least five ionizable groups per facet for binding to occur. As such, this study reveals important mechanistic insight underlying an ND-based pH-controlled therapeutic platform.

Published
2024
Full Text
View/download PDF

6. Advanced Liver Fibrosis Predicts Liver Outcomes in Biopsy-proven Metabolic Dysfunction-associated Steatotic Liver Disease: A U.S.-based Single-center Retrospective Cohort Study.

Author

Lam R, Jain D, Deng Y, Acharya E, and Lim JK

Abstract

Background and Aims: Data regarding risk factors and long-term outcomes of U.S. patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. This study aimed to investigate the role of clinical and histologic risk factors on long-term outcomes in patients with MASLD., Methods: A retrospective cohort study of 451 adults with biopsy-proven MASLD was conducted at a U.S. academic hospital from 2012 to 2020. An experienced pathologist evaluated the index liver biopsy. Patients with a prior liver transplant or alternative etiologies of chronic liver disease were excluded. The duration of the risk exposure was determined from the date of the index liver biopsy to an outcome event or the last follow-up examination. Outcome events of interest included incident liver-related events, liver decompensation, and all-cause mortality., Results: In the final cohort of 406 patients followed for a median of 3.7 years (interquartile range: 4.8 years), 35 patients died, 41 developed hepatic decompensation, and 70 experienced a liver-related event. Among histologic risk factors, stage 3 (adjusted Hazard ratio (aHR) 2.68, 95% confidence interval (CI) 1.18-6.11) and stage 4 (aHR 6.96, 95% CI 3.55-13.64) fibrosis were associated with incident liver-related events compared to stage 0-1 fibrosis. Stage 4 (aHR 8.46, 95% CI 3.26-21.99) fibrosis alone was associated with incident liver decompensation events compared to stage 0-1 fibrosis. Among clinical risk factors, hypertension (aHR 2.58, 95% CI 1.05-6.34) was associated with incident liver decompensation., Conclusions: In a U.S. single-center cohort of patients with biopsy-proven MASLD, advanced fibrosis was the primary risk factor for incident liver decompensation and liver-related events., Competing Interests: JKL has received research contracts (to Yale University) from Gilead, Intercept, Inventiva, Novo Nordisk, Pfizer, and Viking; JKL has been an Executive Associate Editor of Journal of Clinical and Translational Hepatology since 2013. The other authors have no conflict of interests related to this publication., (© 2024 Authors.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results